GlassScriptPhysician profile
Taylor D Smith
NPI 1235745050
$3,347.09
in general payments reported to CMS, 2019-2025
19 companies · $711 in 2025
The $711 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $595 · 2023: $851 · 2024: $824 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.73 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $540.07 | 2022-2025 | |
| Journey Medical Corporation | $492.69 | 2021-2022 | |
| Janssen Biotech, INC. | $421.11 | 2023-2025 | Tremfya |
| Abbvie INC. | $268.26 | 2022-2025 | |
| Dermavant Sciences, INC. | $202.13 | 2022-2024 | Vtama |
| Pfizer INC. | $191.12 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $190.07 | 2023-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $168.11 | 2023-2025 | Dupixent, Libtayo, Evkeeza |
| Galderma Laboratories, L.P. | $158.64 | 2023-2024 | Epsolay |
| Novartis Pharmaceuticals Corporation | $154.91 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.32 | 2023-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $125.00 | 2023 | Ycanth |
| Ucb, INC. | $122.54 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $38.25 | 2023 | Nuedexta, Rexulti |
| Incyte Corporation | $30.71 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $27.70 | 2023 | Impella |
| Organon LLC | $26.93 | 2025 | Vtama |
| Lilly USA, LLC | $21.30 | 2024 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $18.23 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.